Lee Ratner is an Oncology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 631101032
Telephone
800-647-2098Registry record last updated 17 Apr 2025.
Clinical trials
- Nirogacestat in Patients With Kaposi Sarcoma
Sponsor: AIDS Malignancy Consortium
- Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial
Sponsor: Washington University School of Medicine
- Propranolol for the Treatment of Kaposi Sarcoma in Adults
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20221 payment
- Merck Sharp & Dohme LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
29.2%Opioid Agonist19.2%Oxycodone-Acetaminophen100%Part D<11 patientsSSRI10%Escitalopram Oxalate100%Part D<11 patientsAnti-infectives
22.5%Short-acting sulfonamides12.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor10%Valganciclovir Hcl100%Part D<11 patientsCardiovascular
20.8%ACE inhibitor10.8%Lisinopril100%Part D<11 patientsLoop diuretic10%Furosemide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
26 NIH research awards on record, funded 1987–2026 per NIH RePORTER. The latest:
- Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
Washington University
FY2026$360,281R01CA258359 - Project 3: Epigenomic Regulation of HTLV-1 Reactivation & Pathogenesis
Washington University
FY2025$493,051P01CA100730
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”